research use only

Latanoprost Immunology & Inflammation related agonist

Name: Latanoprost
Brand: Selleck Chemicals
SKU: S4709
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S4709

Latanoprost (Xalatan, PhXA41) is a prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. This compound increases uveoscleral outflow and thereby reduces intraocular pressure.

Chemical Structure

Molecular Weight: 432.59

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.89%

99.89

Related Targets	CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor TNF-alpha ROS Parasite PD-1/PD-L1 TLR Prostaglandin Receptor IFN CXCR Nrf2 NOS CCR NLRP3 eIF STING AhR IL Receptor Complement System IRAK β-lactamase IDO/TDO PGES NADPH-oxidase FKBP LTR
Related Products	Cl-amidine (S,S)-TAPI-1 Bindarit Tempol Anti-mouse CD8α-InVivo Tranilast Sinomenine Geniposidic acid GI254023X CORM-3 Bestatin (Ubenimex) Acacetin Germacrone Oxymatrine Gastrodin Atractylenolide I Y-320 Sinomenine hydrochloride Thymoquinone Demethylzeylasteral (T-96) Lupeol Flufenamic acid Quercitrin Laquinimod Iguratimod Calycosin Sanguinarine Punicalagin Z-Guggulsterone Fenamic acid

Chemical Information, Storage & Stability

Molecular Weight	432.59	Formula	C₂₆H₄₀O₅	Storage (From the date of receipt)	2 years -20°C liquid
CAS No.	130209-82-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Xalatan, PhXA41, PHXA-41			Smiles	CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O

Solubility

In vitro
Batch:

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.350mg/ml (10.06mM)	Taking the 1 mL working solution as an example, add 50 μL of 87 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.350mg/ml (10.06mM)	Taking the 1 mL working solution as an example, add 50 μL of 87 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	retinoid X receptor α ^[2] PGF-prostanoid receptor ^[3]
In vitro	Latanoprost functioned as both an indirect activator of AMP-activated protein kinase and a selective retinoid X receptor α (RXRα) antagonist able to selectively antagonise the transcription of a RXRα/peroxisome proliferator-activated receptor γ heterodimer^[2]. This compound induced morphological abnormality and viability decline of HCS cells in vitro. It induces cell cycle arrest of HCS cells. This chemical induces abnormal changes of plasma membrane, DNA fragmentation and ultrastructural abnormality of HCS cells. Caspase activation in HCS cells is also activated by this compound treatment. It induces MTP disruption and quantitative changes of mitochondrion-associated pro-apoptotic regulators in HCS cells^[1]. This compound is effective in inhibiting adipogenesis, reducing lipogenesis, promoting fatty acid oxidation and enhancing GLUT4 translocation and glucose uptake both in adipocytes and myotubes^[2].
In vivo	Latanoprost, a clinical drug for treating primary open-angle glaucoma and intraocular hypertension, effectively ameliorates glucose and lipid disorders in two mouse models of type 2 diabetes. Its treatment improves glucose tolerance. Chronic administration of this compound decreases serum lipids and enhances insulin signalling in white adipose tissue and skeletal muscle. It effectually activates AMPK and regulates glucose and lipid metabolism-relevant genes in diabetic mice^[2].
References	https://pubmed.ncbi.nlm.nih.gov/27749098/ https://pubmed.ncbi.nlm.nih.gov/23989723/ http://www.jbc.org/content/280/41/35028.full

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05333419	Completed	Open Angle Glaucoma\|Ocular Hypertension	PolyActiva Pty Ltd	March 4 2022	Phase 1
NCT02622334	Completed	Glaucoma	Hoffmann-La Roche	December 29 2015	Phase 1
NCT00941525	Completed	Open Angle Glaucoma\|Ocular Hypertension	Aristotle University Of Thessaloniki	September 2009	Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):